IL-MOTOROLA-SOLUTIONS
27.10.2020 14:02:14 CET | Business Wire | Press release
A global pandemic, ever-increasing volumes of data to manage and greater demand to do more with limited resources - the world has never been more complex for public safety agencies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005282/en/
Siloed systems and devices that don’t talk with each other can add to an already existing complexity. First responders need mission-critical technology that offers an intuitive and smart experience to respond effectively in the “heat of the moment,” as well as flexible tools that enable them to connect seamlessly with a broader ecosystem of technologies.
Motorola Solutions is launching its next-generation Terrestrial Trunked Radio (TETRA) device: the smart and powerful MXP600 , to meet the needs of public safety personnel today and well into the future. The lightweight yet highly rugged radio takes the proven capabilities of mission-critical voice communication to new levels and can collaborate with other solutions.
“Frontline professionals will always need their radio in high-stress situations to serve as their lifeline, but they also might require collaboration with other devices that they carry, including smartphones and body worn video cameras, without compromising the security or reliability of their radio voice communications,” said Mark Schmidl, senior vice president at Motorola Solutions.
“Instead of handling multiple devices simultaneously they can activate other devices through the one that feels most natural and intuitive to use in that situation. For example, if a police officer presses the emergency button in a life-threatening situation, the radio will in the future be able to automatically activate the body worn camera, without the officer needing to start the process separately. It's all about simplifying yet elevating key features of mission-critical communications,” explained Katja Millard, senior director devices at Motorola Solutions.
The introduction of the MXP600 will help agencies to flexibly evolve their mission-critical solutions while taking full advantage of the benefits of secure radio voice communications:
- Be clearly heard in the noisiest environments. The MXP600 uses intelligent microphone technology to suppress background noise and has a maximum loudness that is around four times louder than a typical smartphone. When operating in windy conditions, the device automatically uses the loudspeaker as an additional microphone for optimal wind noise mitigation. When multiple radios are in close proximity, the MXP600 automatically eliminates acoustic feedback to allow for effective communication.
- Radically accelerate device management to keep frontline workers in the field. Over-The-Air-Programming (OTAP) makes it possible for radios to be updated on-the-go and within minutes, avoiding the time, logistics and costs involved with traditional radio programming. OTAP is fast, secure and convenient to maximize the productivity of frontline workers and help to keep them in the field.
- Flexible collaboration. Use your radio in the way that suits you best, with a smartphone app for scrolling through talkgroups, sending secure messages and discreet radio communication when you need it. The new M-RadioControl app offers a flexible way for smartphones to work alongside the MXP600. The NFC chip embedded in the MXP600 makes pairing quick and easy, while Bluetooth 5.0 means the wireless connection between radio, smartphone and other devices remains secure.
The MXP600 integrates the technologies emergency services rely upon to focus on their mission to keep the community safe.
Videos
Adaptive Mission-Critical Audio
Designed and Tested for Extreme Conditions
Frontline Safety Today And Tomorrow
Access a media kit with videos and images here .
About Motorola Solutions
Motorola Solutions is a global leader in mission-critical communications and analytics. Our technology platforms in mission-critical communications, command centre software, video security & analytics, bolstered by managed & support services, make communities safer and help businesses stay productive and secure. At Motorola Solutions, we are ushering in a new era in public safety and security. Learn more at www.motorolasolutions.com .
Follow @MotoSolutions on Twitter
Follow @MotorolaSolutions on Instagram
Follow @MotorolaSolutions on LinkedIn
Like @MotorolaSolutions on Facebook
MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license. All other trademarks are the property of their respective owners. ©2020 Motorola Solutions, Inc. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005282/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom